...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Feb. 06, 2019 FMV ZENE!

Management’s Estimate of Fair Value of Common Shares February 6, 2019 To whom it may concern, Management’s estimate of the fair value of the common shares of Zenith Capital Corp. for financial reporting purposes was USD $0.689 per share as at October 31, 2018. If you require further information, please contact Sarah Zapotichny at (403) 254-9252 ex. 875. (signed) “Brad Cann”Brad Cann, CA, CBVChief Financial Officer Zenith Capital Corp.

Share
New Message
Please login to post a reply